Indeterminate results of a tuberculosis-specific interferon-γ release assay in immunocompromised patients

B. Lange; M. Vavra; W. V. Kern; D. Wagner

doi:10.1183/09031936.00122109

Tables

Table 1—

Characteristics of patients and controls and QuantiFERON®–TB Gold in tube results in relation to categorical and continuous variables

	Total	Determinate	Indeterminate	Univariate		Multivariate
	Total	Determinate	Indeterminate	OR (95% CI)	p-value	p-value
Categorical variables: controls
Female	62; 60 (50–69)	61; 98 (95–100)	1; 1.6 (0–7.3)	0	>0.05	>0.05
Male	42; 40 (31–50)	42; 100 (98–100)	(0–6.7)
Categorical variables: patients
Male	258; 58 (53–62)	226; 88 (84–92)	26; 10 (6.4–14)	0.6 (0.4–0.9): male	<0.05	>0.05
Female	189; 42 (38–47)	157; 83 (78–88)	32; 17 (12–23)
Disease group
Organ transplant	233; 52 (48–57)	216; 93 (89–96)	17; 7.3 (4–11)	0.4 (0.2–0.8)	<0.05
Male	157; 67 (61–72)	147; 94 (88–97)	10; 6.4 (3–11)
Female	76; 33 (27–39)	69; 90 (82–96)	7; 9.8 (4–18)
Autoimmune diseases	76; 18 (14–22)	60; 79 (70–88)	16; 21 (12–30)	2.6 (1.4–5.0)	<0.05	0.073
Male	22; 29 (20–40)	22; 100	0; 0
Female	54; 71 (60–80)	38; 70 (57–80)	16; 30 (19–43)
Primary immunodeficiency	45; 10.1 (7.3–13)	41; 91 (83–99)	4; 9 (1–18)	0.8 (0.3–2.3)	>0.05
Male	21; 47 (32–60)	20; 96 (76–100)	1; 4.2 (0–24)
Female	24; 53 (39–67)	21; 87 (68–96)	3; 13 (3–31)
Stem cell transplant	42; 9.4 (6.7–12)	23; 55 (40–70)	19; 45 (30–60)	8.1 (3.0–22)	<0.05	<0.05
Male	25; 60 (44–73)	11; 44 (27–63)	14; 56 (37–73)
Female	17; 40 (27–56)	12; 70 (47–87)	5; 30 (13–53)
HIV patients	51; 11.4 (8.5–14)	49; 96 (91–100)	2; 3.9 (0–10)	2.3 (1.5–4.2)	<0.05
Male	33; 65 (51–76)	32; 97 (83–100)	1; 3 (0–17)
Female	18; 35 (24–49)	17; 94 (72–100)	1; 6 (0–28)
Medication
Steroids	230; 51 (47–56)	195; 85 (80–89)	35; 15.2 (11–20)		>0.05	>0.05
Cyclosporin	147; 33 (29–37)	127; 86 (81–92)	20; 13.6 (8–19)		>0.05	>0.05
Tacrolimus	95; 21 (17–25)	85; 90 (84–96)	10; 10.5 (4–17)		>0.05	>0.05
Methotrexate	25; 6 (4–8)	22; 88 (75–100)	3; 12 (0–25)		>0.05	>0.05
Mycophenolate	173; 39 (34–43)	158; 91 (87–96)	15; 8.7 (4–13)	0.8 (0.7–1.0)	<0.05	>0.05
Risk factors
Diabetes	31; 7 (5–10)	28; 90 (80–100)	3; 9.7 (0–20)		>0.05	>0.05
Smoking	28; 6 (4–9)	26; 93 (83–100)	2; 7.1 (0–17)		>0.05	>0.05
Having had dialysis	206; 46 (42–51)	190; 92 (89–96)	16; 7.8 (4–11)		>0.05	>0.05
Continuos variables: patients
Age yrs	447; 52.4±13.8	389; 52.1±13.7	58; 53.8±14.2		>0.05	>0.05
Erythrocyte count 10⁶·μL⁻¹	431; 4.4±0.7	374; 4.5±0.7	57; 3.9±0.7		<0.05	<0.05
Leukocyte count 1000·μL⁻¹	435; 6.9±3.4	378; 7±3.4	57; 6.4±3.4		>0.05	>0.05
Lymphocyte count μL	305; 1614±836	266; 1691±817	39; 1085±771		<0.05	<0.05
CD3 count μL⁻¹	64; 1114±637	56; 1205±614	8; 481±421		<0.05	<0.05
CD4 count μL⁻¹	78; 462±300	68; 483±289	10; 313±350		>0.05	>0.05
CD8 count μL⁻¹	74; 585±452	64; 656±446	10; 134±90		<0.05	<0.05
Length of dialysis months	196; 56±44	182; 55.1±43	14; 68.5±46		>0.05	>0.05
Length of illness months	413; 91±90	360; 94±88	53; 78±102		>0.05	>0.05

Data are presented as n; % (95% confidence interval) or n; mean±sd, unless otherwise stated. Significant differences in univariate and multivariate analysis are shown in bold. QuantiFERON®–TB Gold in tube is manufactured by Cellestis, Carnegie, Australia.